TapewireFind a company

person · Reporting owner

Freund John Gordon

Disclosed activity across 5 companies

Tapewire entity
40449
SEC CIK
0001296771

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169DirectorMay 18, 2026May 20, 2026
Protara Therapeutics, Inc.PRTO · Entity 6203DirectorNovember 08, 2019November 12, 2019
SI-BONE, Inc.SIBN · Entity 2501DirectorJune 04, 2026June 08, 2026
SUTRO BIOPHARMA, INC.STRO · Entity 5797DirectorJune 06, 2024June 10, 2024
TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285DirectorDecember 10, 2019December 13, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COLLEGIUM PHARMACEUTICAL, INC

Report date May 18, 2026 · Filed May 20, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect83,952 Reported balance After 2026-05-18 transaction · row 1
1 source row

Row 1 · 2026-05-18 · Sale · Disposed 20 · Balance 83,952

Common StockSEC Table I · non-derivativeIndirectBy: John Freund Family Partnership IV, L.P.23,129 Reported balance Holding disclosure · report date 2026-05-18 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 23,129

F1: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy: Skyline Venture Management V, LLC8,625 Reported balance Holding disclosure · report date 2026-05-18 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 8,625

F2: The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.

F2: The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein.

Protara Therapeutics, Inc.

Report date November 08, 2019 · Filed November 12, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,175,882 Reported balance After 2019-11-08 transaction · row 1
1 source row

Row 1 · 2019-11-08 · Conversion · Acquired 703,588 · Balance 2,175,882

F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.99IndirectSee footnote354 Reported balance After 2019-11-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2019-11-08 · Conversion · Disposed 700 · Balance 354

F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Series A Convertible Preferred Stock (the "Series A Stock") are exercisable at any time at the option of the holder into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949. The Series A Stock has no expiration date and contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

F2: On November 8, 2019, Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline") converted 700 shares of Series A Stock, resulting in the issuance to Skyline of 703,558588 shares of Common Stock. The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SI-BONE, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect54,258 Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-04 · Grant · Acquired 10,957 · Balance 54,258

F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.

F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Common StockSEC Table I · non-derivativeIndirectBy John Freund Family Partnership IV, L.P91,767 Reported balance Holding disclosure · report date 2026-06-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 91,767

F3: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.

F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3: Shares held by John Freund Family Partnership IV, L.P. ("Family LP"). Reporting Person, a member of Issuer's board of directors, is a general partner of Family LP and may be deemed to have voting and investment power with respect to the securities held by Family LP. Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

SUTRO BIOPHARMA, INC.

Report date June 06, 2024 · Filed June 10, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2034-06-06Direct35,000 Reported balance After 2024-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-06 · Grant · Acquired 35,000 · Balance 35,000

F1: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 8.33% of the total award monthly, commencing July 6, 2024, with 100% of the award vested and exercisable on the earlier of the date of the issuer's 2025 annual stockholders meeting or June 6, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.

TETRAPHASE PHARMACEUTICALS INC

Report date December 10, 2019 · Filed December 13, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Skyline Venture Management IV, LLC0 Reported balance After 2019-12-10 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2019-12-10 · Sale · Disposed 14,507 · Balance 0

F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. ("SVP IV"). The reporting person is a member of Skyline Venture Management IV, LLC, which serves as the sole general partner of SVP IV, and may be deemed to share voting and dispositive power over the shares held by SVP IV. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-12-10 transaction · row 2
1 source row

Row 2 · 2019-12-10 · Sale · Disposed 524 · Balance 0

F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The numbers of shares of common stock reported on this Form 4 reflects a 1-for-20 reverse stock split effected on September 26, 2019.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.10 to $2.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. ("SVP IV"). The reporting person is a member of Skyline Venture Management IV, LLC, which serves as the sole general partner of SVP IV, and may be deemed to share voting and dispositive power over the shares held by SVP IV. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 19, 2018 Filed Oct 19, 2018 20:48 UTC SI-BONE, Inc. SIBN · Entity 2501 ConversionCommon Stock 2,213,425 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-055697 · doc4.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 2,213,425

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Issuer's Series 4 Preferred Stock, Series 5 Preferred Stock and Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.

F2 · ownership.nature: Shares held by Skyline Venture Partners V, L.P. ("SVP V"). Skyline Venture Management V, LLC ("LLC") is the general partner of SVP V and as such may be deemed to have voting and investment power with respect to the securities of SVP V. Dr. Freund, a member of the Issuer's board of directors, together with Yasunori Kaneko, are the managing directors of LLC and each may be deemed to have voting and investment power with respect to the securities held by SVP V. Dr. Freund disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries E Preferred Stock · Derivative 18,698,578 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 6

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 514,211 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4 · derivative.exercise_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F4 · derivative.expiration_date: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries D Preferred Stock · Derivative 12,846,023 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 5

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 520,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F3 · derivative.exercise_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F3 · derivative.expiration_date: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionSeries C Preferred Stock · Derivative 25,015,635 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · derivative · entry 4

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 925,578 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F1 · derivative.exercise_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F1 · derivative.expiration_date: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 514,211 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · nonDerivative · entry 3

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 1,960,053

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 520,264 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · nonDerivative · entry 2

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 1,445,842

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
October 01, 2018 Filed Oct 1, 2018 21:15 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 ConversionCommon Stock 925,578 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-052835 · doc4.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 925,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

F2 · ownership.nature: These securities are held of record by Skyline Venture Partners V, L.P. ("Skyline L.P."). Skyline Venture Management V, LLC ("Skyline Management") is the general partner of Skyline L.P. the reporting person, a member of the issuer's board of directors, together with Yasunori Kaneko, are the managing directors of Skyline Management, and each may be deemed to share voting and investment power over the securities held by Skyline L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Read SEC document
September 26, 2018 Filed Sep 27, 2018 21:52 UTC SUTRO BIOPHARMA, INC. STRO · Entity 5797 GrantStock Option (right to buy Common Stock) · Derivative 26,033 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001209191-18-052481 · doc4.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,033

Underlying: Common Stock · 26,033 shares

Expires 2028-09-25

F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 20:32 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantStock Option (Right to Buy) · Derivative 12,700 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001171843-18-004580 · formfour.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,700

Underlying: Common Stock · 12,700 shares

Expires 2028-06-07

F1 · derivative.exercise_date: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.

Read SEC document
May 30, 2018 Filed Jun 1, 2018 20:14 UTC TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 GrantStock option (right to buy) · Derivative 12,500 $0.00 Strike: $3.68 $0.00
Disclosure

SEC source: 0001209191-18-034656 · doc4.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2028-05-29

F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant.

Read SEC document
May 24, 2018 Filed May 29, 2018 21:04 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantStock Option (Right to Purchase) · Derivative 4,506 $0.00 Strike: $24.95 $0.00
Disclosure

SEC source: 0001192482-18-000252 · edgar.xml · derivative · entry 4

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,506

Underlying: Common Stock · 4,506 shares

Expires 2028-05-24

F4 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2019, subject to the director's continued service with the issuer.

Read SEC document
May 24, 2018 Filed May 29, 2018 21:04 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantCommon Stock 2,253 $0.00 $0.00
Disclosure

SEC source: 0001192482-18-000252 · edgar.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,253

F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock.

Read SEC document
March 19, 2018 Filed Mar 21, 2018 23:58 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 OtherCommon Stock 8,791 $0.00 $0.00
Disclosure

SEC source: 0001192482-18-000131 · edgar.xml · nonDerivative · entry 2

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Freund Family Partnership IV, L.P.

Disclosed balance after: 20,506

F3 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person.

F4 · ownership.nature: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The reporting person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The reporting person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.

Read SEC document
March 19, 2018 Filed Mar 21, 2018 23:58 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 OtherCommon Stock 600,000 $0.00 $0.00
Disclosure

SEC source: 0001192482-18-000131 · edgar.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 1,549,916

F1 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners.

F2 · ownership.nature: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Freund disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein.

Read SEC document
December 05, 2017 Filed Dec 8, 2017 00:07 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 OtherCommon Stock 11,715 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000306 · edgar.xml · nonDerivative · entry 2

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By John Freund Family Partnership IV, L.P.

Disclosed balance after: 11,715

F3 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to the reporting person.

F4 · ownership.nature: The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The reporting person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The reporting person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.

Read SEC document
December 05, 2017 Filed Dec 8, 2017 00:07 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 OtherCommon Stock 800,000 $0.00 $0.00
Disclosure

SEC source: 0001192482-17-000306 · edgar.xml · nonDerivative · entry 1

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners V, L.P.

Disclosed balance after: 2,149,916

F1 · kind: Represents a pro rata in-kind distribution of the shares by Skyline Venture Partners V, L.P. without consideration to its limited and general partners.

F2 · ownership.nature: The shares are held by Skyline Venture Partners V, L.P. The general partner of Skyline Venture Partners V, L.P. is Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management, LLC. Dr. Freund disclaims beneficial ownership of all the shares held by Skyline Venture Partners V, L.P. except to the extent of his proportionate pecuniary interest therein.

Read SEC document
June 22, 2017 Filed Jun 26, 2017 21:27 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 PurchaseSeries A Convertible Preferred Stock · Derivative 1,054 $1,000.00 Strike: $0.99 $1,054,000.00
Disclosure

SEC source: 0001171843-17-003831 · form4freund.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Skyline Venture Partners

Disclosed balance after: 1,054

Underlying: Common Stock, $0.001 par value · 1,059,403 shares

Expires not disclosed

F1 · derivative.exercise_price: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949.

F1 · derivative.exercise_date: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.001 par value per share (the "Common Stock"), at a price per share equal to $0.9949.

F3 · derivative.exercise_date: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

F2 · derivative.expiration_date: The Series A Stock has no expiration date.

F3 · derivative.underlying_shares: The Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.

F4 · ownership.nature: The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV, LP. ("Skyline").

F5 · ownership.nature: The reporting person is a Managing Director of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
June 20, 2017 Filed Jun 21, 2017 20:16 UTC Protara Therapeutics, Inc. PRTO · Entity 6203 GrantStock Option (Right to Buy) · Derivative 6,666 $0.00 Strike: $1.30 $0.00
Disclosure

SEC source: 0001171843-17-003743 · formfour.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,666

Underlying: Common Stock, $0.001 par value · 6,666 shares

Expires 2027-06-19

F1 · derivative.exercise_date: The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders.

Read SEC document
May 31, 2017 Filed Jun 1, 2017 21:01 UTC TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 GrantStock option (right to buy) · Derivative 12,500 $0.00 Strike: $6.89 $0.00
Disclosure

SEC source: 0001209191-17-036839 · doc4.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2027-05-30

F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant.

Read SEC document
May 24, 2017 Filed May 25, 2017 20:20 UTC COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 GrantStock Option (Right to Purchase) · Derivative 19,853 $0.00 Strike: $9.33 $0.00
Disclosure

SEC source: 0001192482-17-000131 · edgar.xml · derivative · entry 1

Freund John Gordon · CIK 0001296771 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,853

Underlying: Common Stock · 19,853 shares

Expires 2027-05-24

F1 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2018, subject to the director's continued service with the issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.